High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas

  • Wang, Yao-Wu (Department of Neurosurgery, The Second Hospital of Hebei Medical University) ;
  • Yin, Chun-Li (Department of Neurosurgery, Tangshan Gongren Hospital) ;
  • Zhang, Hong-Yi (Department of Neurosurgery, Tangshan Gongren Hospital) ;
  • Hao, Jin-Min (Department of Neurosurgery, The Second Hospital of Hebei Medical University) ;
  • Yang, Yue-Ye (Department of Neurosurgery, Tangshan Gongren Hospital) ;
  • Liao, Heng (Department of Neurosurgery, Tangshan Gongren Hospital) ;
  • Jiao, Bao-Hua (Department of Neurosurgery, The Second Hospital of Hebei Medical University)
  • Published : 2015.01.22


Background: Increasing evidence has indicated that high Forkhead box protein C2 (FOXC2) level is closely associated with the development, progression, and poor prognosis of a variety of tumors. However, the relationship between FOXC2 and the progression of human gliomas remains to be clarified. The aim of present study was to assess FOXC2 expression and to explore its contribution in human gliomas. Materials and Methods: Realtime quantitative PCR was performed to examine FOXC2 expression in 85 pairs of fresh frozen glioma tissues and corresponding non-neoplastic brain tissues. Associations of FOXC2 expression with clinicopathological factors and prognosis of glioma patients were statistically analyzed. Results: The relative mRNA expression of FOXC2 was significantly higher in glioma tissues than the corresponding non-neoplastic brain tissues (p<0.001). In addition, high FOXC2 expression was significantly associated with advanced pathological grade (P=0.005) and the low Karnofsky performance score (KPS) (p=0.003), correlating with poor survival (p<0.001). Furthermore, multivariate Cox regression analysis showed that high FOXC2 expression was an independent predictor of overall survival (p=0.006). Conclusions: FOXC2 may act as an oncogenic gene and represent a potential regulator of aggressive development and a candidate prognostic marker in human gliomas.


  1. Bansal K, Liang ML, Rutka JT (2006). Molecular biology of human gliomas. Technol Cancer Res Treat, 5, 185-94.
  2. Feng B, Hu P, Lu SJ, et al (2014). Increased argonaute 2 expression in gliomas and its association with tumor progression and poor prognosis. Asian Pac J Cancer Prev, 15, 4079-83.
  3. Hollier BG, Tinnirello AA, Werden SJ, et al (2013). FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res, 73, 1981-92.
  4. Jiang W, Pang XG, Wang Q, et al (2012). Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer, 13, 280-7.
  5. Kume T (2008). Foxc2 transcription factor: a newly described regulator of angiogenesis. Trends Cardiovasc Med, 18, 224-8.
  6. Kume T (2012). The role of FoxC2 transcription factor in tumor angiogenesis. J Oncol, 2012, 204593.
  7. Li W, Fu X, Liu R, et al (2013). FOXC2 often overexpressed in glioblastoma enhances proliferation and invasion in glioblastoma cells. Oncol Res, 21, 111-20.
  8. Liu B, Han SM, Tang XY, et al (2014). Overexpressed FOXC2 in ovarian cancer enhances the epithelial-to-mesenchymal transition and invasion of ovarian cancer cells. Oncol Rep, 31, 2545-54.
  9. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.
  10. Mani SA, Yang J, Brooks M, et al (2007). Mesenchyme forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA, 104, 10069-74.
  11. Meyer MA (2008). Malignant gliomas in adults. N Engl J Med, 359, 1850.
  12. Nishida N, Mimori K, Yokobori T, et al (2011). FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol, 18, 535-42.
  13. Reni M, Mazza E, Tosoni A, et al (2005). Novel therapeutics in adult malignant brain gliomas. Expert Opin Investig Drugs, 14, 643-58.
  14. Van Meir EG, Hadjipanayis CG, Norden AD, et al (2010). Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin, 60, 166-93.
  15. Watanabe T, Kobunai T, Yamamoto Y, et al (2011). Gene expression of mesenchyme forkhead 1 (FOXC2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int Surg, 96, 207-16.
  16. Wu X, Liu NF (2011). FOXC2 transcription factor: a novel regulator of lymphangiogenesis. Lymphology, 44, 35-41.
  17. Zheng CH, Quan Y, Li YY, et al (2014). Expression of transcription factor FOXC2 in cervical cancer and effects of silencing on cervical cancer cell proliferation. Asian Pac J Cancer Prev, 15, 1589-95.
  18. Zhu JL, Song YX, Wang ZN, et al (2013). The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology, 62, 1038-48.

Cited by

  1. Preoperative Grading of Astrocytic Supratentorial Brain Tumors with Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient vol.13, pp.3, 2016,
  2. Induction of epithelial to mesenchymal transition (EMT) and inhibition on adipogenesis: Two different sides of the same coin? Feasible roles and mechanisms of transforming growth factor β1 (TGF-β1) in age-related thymic involution vol.40, pp.8, 2016,
  3. Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism vol.12, pp.6, 2016,
  4. A Forkhead Box Protein C2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis vol.19, pp.13, 2018,